Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Wistuba

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Nature|May 25, 2017
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cellsJiyeon Kim, Zeping Hu, Ling Cai, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Nature|May 3, 2019
Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cellsJiyeon Kim, Zeping Hu, Ling Cai, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytesParin Shah, Marie-Andrée Forget, Meredith L Frank, et al.
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trialGeorge R Blumenschein, Pierre Saintigny, Suyu Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectMing Sound Tsao, Keith M Kerr, Mark Kockx, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Nature|May 25, 2017
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cellsJiyeon Kim, Zeping Hu, Ling Cai, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Nature|May 3, 2019
Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cellsJiyeon Kim, Zeping Hu, Ling Cai, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytesParin Shah, Marie-Andrée Forget, Meredith L Frank, et al.
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trialGeorge R Blumenschein, Pierre Saintigny, Suyu Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectMing Sound Tsao, Keith M Kerr, Mark Kockx, et al.
Pageof 13